Fennec Pharmaceuticals Inc. (FRX.TO)
Fennec Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Research Triangle Park, NC, US. The stock last traded at $16.77, down 4.88% on the session, giving a market capitalisation of $582.5M. Its beta of 1.07 implies it has historically moved more than the broad market.
Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.
Fennec Pharmaceuticals Inc. is most often compared with the following Healthcare names: